SA
FLGT icon

Strategic Advocates’s Fulgent Genetics FLGT Stock Holding History

Strategic Advocates’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-534
Closed -$14.1K – 385
2025
Q4 		$14.1K Sell
534
-88
-14% -$2.28K ﹤0.01% 331
2025
Q3 		$14.1K Buy
+622
New +$12.8K ﹤0.01% 327

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Strategic Advocates's FLGT Position: Q1 2026 in Review

Strategic Advocates sold out of Fulgent Genetics (FLGT) in Q1 2026, closing a stake of 534 shares — an estimated $14.1K sold.

Strategic Advocates first reported a position in FLGT in Q3 2025 and held it in 2 quarters. The position peaked at $14.1K in Q4 2025. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Strategic Advocates reported no remaining Fulgent Genetics position as of Q1 2026 after selling out during the quarter.
  • Strategic Advocates sold 534 Fulgent Genetics shares in Q1 2026, an estimated $14.1K.
  • Strategic Advocates first reported a position in Fulgent Genetics in Q3 2025 and held it in 2 quarters.
  • Strategic Advocates's Fulgent Genetics position peaked at $14.1K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.